System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Prof François Ghiringhelli is an expert in Oncology at Centre Georges François Leclerc (France). As of October 2026, ScienceLeadR ranks François Ghiringhelli in the top 1% of experts worldwide for Intestinal Neoplasms, Rectal Diseases and Gastrointestinal Neoplasms. François Ghiringhelli has authored 752 publications, the most recent in 2027, and is an investigator in 134 clinical trials, 59 of them ongoing. SLR score: 4,935 (community average: 125). How the SLR is computed.

LeadR Profile

Prof François Ghiringhelli Centre Georges François Leclerc France
4 935 ScienceLeadR Reputation 4935

Unlock

Register Login
Network Map

Oncology

Subspecialties: Immunology - Biochemistry - Pharmacy

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2004 - 2027
Source: PubMed

INSERM

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 752

Citations

Citations: 65 537 1st author: 53 Last author: 182 Unique author: 6

Main journals

J Clin Oncol 82
Ann Oncol 66
Cancer Res 36
Eur J Cancer 23
Oncoimmunology 23

Best Journals

J Clin Oncol 49
Ann Oncol 45
Science 6

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Usability and relevance of specialized population-based cancer registry data in externally controlled trials.
PMID 42556756 — registries, epidemiology, neoplasms, propensity score		J Clin Epidemiol20260
Understanding Venous Remodeling After Minimally Invasive and Noninvasive Treatments for Varicose Veins: A Mechanistic Narrative Review.
PMID 42930610 — immunohistochemistry, fibrosis, adhesives, therapeutics, tissues, varicose veins, veins		Med Sci (Basel)20260
Reference frame for Adult Brainstem gliomas.
PMID 42860045 — glioma, neoplasms, biopsy, brain stem, diagnosis, therapeutics		Oncologist20260
EGFR Targeting With Afatinib and Cetuximab Versus Cetuximab Alone in Chemorefractory Wild-type RAS Metastatic Colorectal Cancer: A Randomized Phase II Study With Circulating Tumor Cell Analysis.
PMID 42859101 — cells, cetuximab, neoplastic cells, circulating, neoplasms, afatinib, colorectal neoplasms		Clin Colorectal Cancer20260
An integrated Phase II/III randomized study comparing durvalumab and tremelimumab ± Hepatic ArteriaL infusion chemotherapy with GEMOX in hepatocellular Carcinoma with high tumor burdEn - ALICE (PRODIGE89 - UCGI44 - ALICE).
PMID 42736101 — carcinoma, hepatocellular, safety, neoplasms, drug therapy, tumor burden, chemotherapy		Dig Liver Dis20260

Clinical Studies 134

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 13 Study Director: 1

By phase:

Phase 2 58
Phase 1/Phase 2 25
Phase 3 18
N/A 11
Phase 2/Phase 3 11
Phase 1 10
Phase 4 1

By status:

Recruiting 49
Completed 42
Active not recruiting 16
Terminated 12
Unknown 9
Not yet recruiting 5
Withdrawn 1

By type:

Interventional 131
Observational 3

By Monocentric/Multicentric:

monocentric 15
multicentric2to4 12
multicentric5to9 25
multicentricup10 82

Main Topics

Cohort/Consortium Investigators 8

Ongoing Clinical Trials

59 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy Based Treatment Combinations in Patients with Advanced Liver Cancers (Morpheus Liver)
2023-506611-17-00 — safety, neoplasms, liver, immunotherapy, liver neoplasms, therapeutics		Phase 1/Phase 2Recruiting2026
A Phase 1 Study Investigating the Safety Tolerability Pharmacokinetics Pharmacodynamics and Preliminary Antitumor Activity of BGB B2033 Alone or in Combination With Tislelizumab With or Without Bevacizumab in Participants With Selected Advanced or Metastatic Solid Tumors
2025-524136-19-00 — safety, neoplasms, bevacizumab, pharmacokinetics		Phase 1Recruiting2026
AMG 436 as monotherapy and combination therapy in participants with Microsatellite Instability High Mismatch Repair Deficient Solid Tumors
2025-524056-63-00 — dna mismatch repair, microsatellite repeats, neoplasms, therapeutics, microsatellite instability, mmr-deficient, msi-h		Phase 1Recruiting2026
Study of Intravenous Telisotuzumab Adizutecan in Combination With a PD 1 Immune Checkpoint Inhibitor to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced or Metastatic Non Squamous NSCLC
2024-514465-18-00 — lung, safety, multiple chronic conditions, carcinoma, non-small-cell lung, drug-related side effects and adverse reactions, immune checkpoint inhibitors, therapeutics		Phase 1/Phase 2Recruiting2025
Beamion BCGC 1 A study to find a suitable dose of zongertinib used alone and in combination with other treatments to test whether it helps people with different types of HER2 cancer that has spread
2023-509566-38-00 — breast neoplasms, esophagogastric junction, neoplasms, adenocarcinoma, breast, therapeutics, colorectal neoplasms, capecitabine, trastuzumab		Phase 1/Phase 2Recruiting2024

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS